Remote Ischemic Conditioning for Neonatal Hypoxic-Ischemic Encephalopathy: A Safety and Feasibility Trial

Emily Lo¹, Mehmet N. Cizmeci¹, Diane Wilson¹, Linh G. Ly¹, Amr El-Shahed¹, Martin Offringa²,³, Agostino Pierro⁴,⁵,⁶, Brian T. Kalish¹,⁷,⁸#

¹Division of Neonatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, M5G 1X8, Canada
²Child Health Evaluative Sciences, SickKids Research Institute, 686 Bay Street, Toronto, ON M5G 1L7, Canada
³Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, M5S 1A1, Canada
⁴Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada
⁵Translational Medicine, SickKids Research Institute, 686 Bay Street, Toronto, ON M5G 1L7, Canada
⁶Division of General and Thoracic Surgery, The Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada
⁷Department of Molecular Genetics, University of Toronto, 555 University Avenue, Toronto, ON, M5G 1X8, Canada
⁸Program in Neuroscience and Mental Health, SickKids Research Institute, 686 Bay Street, Toronto, ON M5G 1L7, Canada

#Lead contact: brian.kalish@sickkids.ca

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
ABSTRACT

Objective: To test the hypothesis that remote ischemic conditioning (RIC) is safe and feasible as an adjunctive neuroprotective treatment in neonates with hypoxic-ischemic encephalopathy (HIE) during therapeutic hypothermia (TH).

Study design: In this prospective, randomized, safety and dose escalation study in 32 neonates with HIE undergoing TH at a single quaternary referral NICU, four cohorts of consecutive patients received escalating therapy as follows: the first cohort of four patients received 3 minutes of limb ischemia by inflating a blood pressure cuff followed by 3 minutes of reperfusion; the second cohort of four patients received 5 minutes of limb ischemia followed by 5 minutes of reperfusion; the third cohort of four patients received 5 minutes of limb ischemia followed by 5 minutes of reperfusion on days 1 and 2 of TH; and the last cohort of four patients received 5 minutes of limb ischemia followed by 5 minutes of reperfusion on days 1, 2, and 3 of TH. For patients randomized to the control arm (n=16), a blood pressure cuff was applied without inflation. Each patient received 4 cycles of RIC or sham. Clinical, biochemical, and safety outcomes were monitored in both groups.

Results: All patients received the designated RIC therapy without interruption or delay on days 1-3 of TH. RIC was not associated with increased pain, vascular, cutaneous, muscular, or neural safety events. There was no difference in the incidence of seizures, brain injury, or mortality between the two groups with the escalation of RIC dose and frequency.

Conclusion: RIC is a safe and feasible adjunctive therapy for neonates with HIE undergoing TH. Future studies to investigate the potential efficacy of RIC for HIE are warranted.
INTRODUCTION

Hypoxic-ischemic encephalopathy (HIE) is a potentially devastating neurological condition in neonates that results from a peripartum disruption in blood flow and oxygen delivery to the fetus. HIE is estimated to affect 1.5 per 1000 live births worldwide, making it a leading cause of neonatal morbidity and mortality (1). Despite the implementation of therapeutic hypothermia (TH) as the standard of care for infants with moderate-severe HIE, approximately 50% of infants with HIE die or have neurodevelopmental impairment (2). Survivors have increased risk of seizure disorders, hearing loss, and vision loss (3). Thus, novel adjunctive strategies are urgently needed to provide neuroprotection after HIE.

Here, we propose remote ischemic conditioning (RIC) as a potential neuroprotective adjunct in infants with HIE. RIC is a maneuver that creates transient cycles of ischemia and reperfusion to a remote site (e.g. limb), typically through extended and repeated inflation of a standard blood pressure cuff. The goal is to protect the organ exposed to ischemia, such as the brain, from further injury by inducing non-lethal ischemia in the remote site. Clinical trials in adults with acute ischemic stroke have found that RIC was associated a reduction in the area of infarct and the incidence of recurrent strokes, as well as with improved neurological outcomes, albeit with heterogeneous effects, likely secondary to patient selection and RIC implementation (4–6). This is consistent with preclinical rodent studies of stroke where RIC significantly reduced the extent of ischemia and neurological deficits (7). Furthermore, RIC was found to be safe and feasible in neonates of younger gestational age and lower birth weight (8). However, the effects of RIC on neonates with HIE undergoing TH has not been explored. We propose that RIC may be a promising adjunctive therapeutic option to improve neurodevelopmental outcomes.
Therefore, the objective of this study was to assess the safety and feasibility of RIC in neonates with HIE.

**METHODS**

This was a single-site, single-blinded, prospective, and randomized controlled trial of RIC in neonates with HIE undergoing TH. Patients were enrolled between January 2022 to January 2024. The trial was approved by the Research Ethics Board (REB) at The Hospital of Sick Children (REB #1000077295) and registered with ClinicalTrials.gov (NCT05379218). Informed consent was obtained from parent or legal guardian for all participants.

**Participants**

Neonates who were admitted to the NICU with a diagnosis of HIE and who qualified for TH based on the attending neonatologist’s assessment were eligible for enrollment. The flow diagram of patients in the study is shown in Figure 1. In the current TH protocol for HIE at the Hospital for Sick Children, infants who qualify for TH should fulfill the following criteria: gestational age greater than or equal to 35 weeks, less than 6 hours of life, evidence of intrapartum hypoxia defined as either cord or postnatal gas within one hour of birth with pH ≤ 7 or base deficits ≥ -16 or if pH 7.01-7.15 or base deficit -10 to -15 with acute perinatal event, and signs of moderate to severe encephalopathy or seizures; the ultimate decision to proceed with TH is based on the neonatologist’s discretion. Exclusion criteria were as follows: infants with gestational age <35 weeks, known central nervous system malformations, known chromosomal or genetic anomalies, confirmed or suspected inborn errors of metabolism, parental decision for withdrawal, patients requiring significant hemodynamic support (two or more blood pressure support agents, epinephrine infusion >0.05 mcg/kg/min, or vasopressin >0.1 mU/kg/min) for the
four hour period prior to RIC, and infants requiring inhaled nitric oxide or fraction of inspired oxygen (FiO2) >0.50 for the four hour period prior to RIC.

**Randomization and dose escalation**

Patients were randomized and allocated to the RIC intervention or control arm by sequentially numbered, opaque, and sealed envelopes. For patients randomized to the RIC arm, cohorts of four consecutive patients received escalating therapy:

(A) Four consecutive patients had four cycles of three minutes of ischemia, followed by five minutes of reperfusion on day 1 of TH.

(B) Observing no safety events from the patients in group (A), four consecutive patients had four cycles of five minutes of ischemia, followed by five minutes of reperfusion on day 1 of TH.

(C) Observing no safety events from patients in group (B), four consecutive patients had four cycles of five minutes of ischemia, followed by five minutes of reperfusion on day 1 and 2 of TH.

(D) Observing no safety events from patients in group (C), four consecutive patients had four cycles of five minutes of ischemia, followed by five minutes of reperfusion on day 1, 2, and 3 of TH.

Enrolled patients had the first RIC or sham procedure performed within 24 hours of TH initiation.

**Procedure**
For patients randomized to the RIC intervention arm, an appropriately sized manual blood pressure cuff and a pulse oximeter probe were applied on an arm or leg and inflated and deflated to administer ischemia-reperfusion cycles. The limb selected for RIC was free from intravenous or intra-arterial catheters. Cycles of ischemia and reperfusion were achieved with the inflation and deflation of a manual blood pressure cuff. This cuff was inflated 20 mm Hg above the participants’ systolic blood pressure as measured by an arterial line and/or manual blood pressure cuff. To ensure that adequate ischemia was achieved, loss of the pulse oximeter probe signal was required. If loss of pulse oximeter probe signal was not achieved, the inflation pressure was increased by 5 mm Hg every 10 seconds until loss of pulse oximeter probe signal. The timing of inflation and deflation was dependent on the cohort group (A-D), as described above. For patients randomized to the control arm, a blood pressure cuff and pulse oximeter probe were applied to a limb, but the cuff was not inflated.

**Primary Outcome: Feasibility and Safety Assessments**

Intervention feasibility was defined as the ability to complete RIC in a dose escalation therapy in neonates undergoing TH. Several safety parameters, including pain, vascular, cutaneous, muscular, and neural components, were assessed prior, during, and after the ischemia-reperfusion cycles. Pain was measured by the Premature Infant Pain Profile (PIPP) score 15 minutes prior to the first cycle, 30-60 seconds after each cycle, and 15 minutes and 6 hours after the last cycle. Vascular limb components were assessed by perfusion (capillary refill time) and return of pulse oximetry wave 60-90 seconds after every cuff deflation. Cutaneous limb components were assessed by visual inspection of the skin for wounds, skin excoriations, petechiae, and/or hematomas after every cycle and 24 hours after the last cycle of ischemia-
reperfusion. Muscular limb components were assessed through laboratory markers of potassium, phosphate, and creatinine as muscle ischemia can result in metabolic (hyperkalemia, hyperphosphatemia) and renal disturbances. Laboratory measurements were done at 24, 48, and 72 hours of TH as per the TH protocol. Laboratory measurements were collected +/- 8 hours from the 24, 48, and 72 hours time points. If there was missing data at the 72-hour time point, the 48-hour laboratory values were collected and used for statistical analysis. Neural limb components were assessed by eliciting grasp reflexes before the first cycle, immediately after RIC, and 24 hours after the last RIC cycle.

**Criteria for acute RIC Interruption and Rescue Interventions**

The maneuver was stopped if the arm/leg undergoing RIC showed absence of return of perfusion by clinical inspection or absence pulse return by pulse oximetry reading within the reperfusion time of 5 minutes. If either of these events occurred, no additional RIC cycles were applied to the patient. If the perfusion does not return after the expected reperfusion time, escalation of rescue interventions include: rewarming the limb for 5 minutes, elevating the limb for 5 minutes, applying a nitroglycerine patch over the skin area covered by the cuff, requesting for a doppler ultrasound, and requesting for a thrombosis consult.

**Brain MRI Assessments**

All newborns underwent brain MRI as part of the routine clinical care that followed the institutional guidelines. The MRI scans were acquired on 3 Tesla (Magnetom Skyra, Siemens Healthcare Limited, Germany) scanners with an age-appropriate head coil. The 3D sagittal T1-weighted images were acquired with a slice-thickness of 0.5 mm, resolution 0.4018 mm x 0.4018
mm, echo time 3.52 ms, repetition time 2200 ms, while the 2D T2-weighted volumes were acquired with a slice thickness of 3 mm, in-plane resolution 0.5 mm x 0.5 mm, echo time 186 ms and the repetition time 5330 ms. The aimed timing of the MRI scans was on days 4 to 5 after birth, after the completion of the rewarming phase of TH. An experienced reviewer officially trained in neonatal neurology and neuroimaging (MNC) who was blinded to the clinical data systematically assessed and scored the MRI scans for the pattern of WM and DGM abnormalities by using a validated brain injury scoring system developed by Weeke et al (9). The cumulative score for DGM, MR-spectroscopy metrics, WM and cortical regions, cerebellum, and additional findings on brain MRI was calculated to obtain a total brain injury score ranging from 0 to 55 points, with higher scores reflecting greater severity of brain abnormalities.

**Statistical Methods**

Statistical analyses were performed on R (version 4.3.2). An unpaired two-tailed Student’s t-test or Wilcoxon rank-sum test was used to compare continuous variables and a chi-square test or Fisher’s exact test was used to compare categorical variables between the control and RIC groups. Continuous variables were plotted and tested for normality. Continuous variables were presented as mean (± standard deviation [SD]). Categorical variables were presented as numbers and percentages. P value <0.05 was considered statistically significant. P value <0.05 was considered statistically significant.

**Data Safety and Monitoring**

A Data Safety and Monitoring Board (DSMB) consisting of pediatric cardiologists and critical care intensivists convened 4 times during the clinical trial to review the interim safety data on all
patients after completion of each block of 8 patients. Enrollment was paused until the DSMB determined it was safe and feasible to proceed to the next dose cohort.

RESULTS

Out of 114 eligible patients, thirty-two neonates were recruited in this study in a blocked treatment assignment of 8 patients (4 in RIC and 4 in control) in each cohort (Figure 1). The baseline and clinical characteristics of these patients are shown in Table 1. There was no significant difference in gestational age (39 ± 1.2 versus 39.5 ± 1.4 weeks), birth weight (3416 ± 701 versus 3617 ± 525 grams), and perinatal variables, including Apgar scores and cord gases, between the control and RIC groups. The Modified Sarnat scores on admission were not different between the two groups.

Primary Outcomes: RIC Feasibility and Safety

RIC cycles were administered as planned, including within 24 hours of TH initiation, in all neonates. The clinical outcomes between the control and RIC groups are shown in Table 2. There were no incidences of absence of return of perfusion, RIC interruption and need for rescue intervention in either the control or RIC groups. While there were two incidences of subcutaneous fat necrosis and two incidences of AKI (stage 2 and stage 3) in the control group, there were no incidences in the RIC group. The incidence of seizures (clinical or subclinical) was comparable between the control and RIC groups (10 versus 9 infants, p=0.296). Similarly, mortality was comparable between the control and RIC groups (4 versus 5 infants, p=1.00).
Secondary Outcomes

There were no incidences of cutaneous injury, including skin breakdown, bruising, ecchymosis, or petechiae, or neural injury, including loss of grasp reflexes, in either group. There was also no difference in need for analgesia after RIC or sham (1 in each arm).

The physiological changes during RIC or sham are shown in Table 4; these clinical parameters are displayed in Figures 2-3. There was no statistical difference in oxygen saturation, capillary refill time, and PIPP scores pre- and post-maneuver between the control and RIC groups across all cohorts. Similarly, there was no statistical significance in the biochemical markers between the control and RIC group at 24 hours and at 48 to 72 hours, with the exception of creatinine which was higher in the control group compared to the RIC group at 24 hours (83 ± 31 versus 61 ± 13 µmol/L, p=0.021) and at 48 to 72 hours (94 ± 47 versus 39 ± 8 µmol/L, p=0.016).

The brain MRI injury scores are shown in Table 5. The total brain injury score was similar across the groups (8.6 ± 9.7 versus 10.6 ± 10.0, p=0.427). There was no significant difference in the total injury score or the subscores for basal ganglia/thalami, basal ganglia/thalami and proton magnetic resonance spectroscopy (H-MRS), white matter, cerebellar, and additional (intraventricular, subdural hemorrhage, cerebral venous sinus thrombosis) injury between the control and RIC groups.

DISCUSSION

To our knowledge, this is the first clinical trial evaluating the safety and feasibility of RIC in neonates with HIE undergoing TH. We found that the administration of escalating
duration and frequency of RIC during TH was both safe and feasible. Importantly, it was possible to consent caregivers and administer RIC within 24 hours of TH initiation. There were no significant adverse events associated with RIC, including increased pain, vascular, cutaneous, muscular or neural injury, nor were there any differences in seizure burden or mortality. This study was not powered or designed to measure efficacy, but our results provide a critical foundation for the design and implementation of future trials of RIC concomitantly with TH.

RIC has been extensively studied in adults in the context of acute ischemic stroke, where clinical trials have evaluated both pre-hospital and hospital-based RIC interventions (6,10). Evidence for efficacy of RIC in improving neurologic outcome after stroke has been mixed, but in the largest trial of RIC for ischemic stroke, RIC was associated with a greater likelihood of excellent functional outcome at 90 days after symptom onset (6). RIC duration and frequency, as well as patient selection, are key determinants of variability observed in neuroprotection.

RIC likely exerts neuroprotection through several overlapping mechanisms involving neuronal, humoral, and systemic effects (11,12). In the neuronal pathway, the activation of afferent nerves and the release of neuropeptides at the site of RIC act on the efferent nerves at the larger site of ischemia to offer protection (11). The protective effects appear to diminish with the administration of ganglion blockades and nerve resections (13–15). The humoral pathway involves the release of hydrophobic factors that travel from the site of RIC to the site of ischemia for protection (11,12). While the exact constitution of factors remains largely unknown, adenosine, bradykinin-2, and opioids are potential mediators of RIC neuroprotection (11,16–18). Recently, preclinical evidence suggests that two key humoral factors – glucagon-like peptides (GLP) and stromal cell derived factor-1a (SDF-1a) – may be important effectors of RIC organ protection. Both GLP and SDF-1a may increase neurogenesis, reduce cell death, and dampen
inflammation (19–22). Importantly, the systemic pathway of RIC benefit likely also involves the
modification of the immune system in response to RIC (11), as induction of a homeostatic
immune state may promote brain repair. Questions to be addressed include the optimal timing of
RIC administration related to the hypoxic ischemic injury, optimal duration, and frequency (i.e.,
the total RIC dose) for infants in the first days of their HIE.

The main limitation of our study is the small sample size due to its design as a safety and
feasibility trial. As such, the current analyses of seizure burden, neuroimaging, and mortality are
unable to discern potential immediate benefits of RIC. Future studies with larger cohorts will be
needed to determine the potential efficacy of RIC to reduce neurodevelopmental impairment. To
enhance recruitment into such future studies, efforts for provider education are required to
improve the generalizability of RIC for HIE, as are efforts to improve evidence dissemination
and family engagement through patient advocacy groups.

**Conclusion:**

In this pilot randomized control trial, we found that RIC is safe and feasible in neonates with HIE
undergoing TH. Future studies are necessary to investigate the efficacy of RIC in reducing brain
injury and improving neurodevelopmental outcomes after HIE.

**Acknowledgements:** We would like to thank members of the Data Safety and Monitoring Board
(Michael Seed, Mjaye Mazwi, and Andrew Helmers) for their contribution.

**Funding:** This study was supported by internal research funds to BTK from the Hospital for
Sick Children.
**Disclosures:** The authors have no conflicts of interests to declare. The funder had no role in the design or conduct of the study.
References


